胃旁路术治疗胃食管反流症状的长期结局:全国性队列研究
该研究基于瑞典2006至2015年接受胃旁路术的2454例术前有反流症状的成人,随访至2016年。术后2年内48.8%的患者反流复发,并持续至术后10年;术前抗反流药物剂量高、年龄>50岁、女性及合并症为复发危险因素。作者认为胃旁路术对反流症状的疗效可能被高估。
要点
- 胃旁路术后2年内48.8%患者反流复发,并稳定持续至术后10年。
- 术前抗反流药物剂量高者复发风险为低剂量者的1.77倍(IRR 1.77)。
- 女性、年龄>50岁及Charlson合并症指数≥2与反流复发风险升高相关。
核心结论
- 胃旁路术后反流症状快速减少,但约半数手术患者需持续使用抗反流药物,作者认为胃旁路术对反流症状的治疗效果可能被高估。
研究设计与样本
- 瑞典全国性队列研究,纳入2006至2015年接受胃旁路术的所有术前有反流的成人,随访至2016年完整覆盖。
- 共纳入2454例参与者(女性81.7%;平均年龄46.1岁,标准差9.8岁),中位随访4.6年(四分位距3.1-6.3年)。
主要发现
- 术后2年内48.8%(95%CI 46.8-51.0)的参与者反流复发,并稳定持续至术后10年(年发病率比变化IRR 1.00;95%CI 0.99-1.02)。
- 与低剂量相比,术前抗反流药物高剂量者反流复发风险IRR 1.77(95%CI 1.60-1.96)。
- 与年龄<40岁相比,年龄>50岁者反流复发风险IRR 1.12(95%CI 1.02-1.24)。
- 女性反流复发风险IRR 1.28(95%CI 1.16-1.42)。
- 与Charlson合并症指数0相比,指数≥2者反流复发风险IRR 1.26(95%CI 1.14-1.39)。
关键数值与推荐
- 反流复发定义为术后使用质子泵抑制剂或组胺-2受体拮抗剂超过6个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastric bypass is considered an effective treatment of co-existing gastro-oesophageal reflux (GERD) and obesity. Previous studies have had small sample sizes, short follow-up or substantial loss to follow-up. AIM: To assess the long-term risk of remaining/recurring reflux symptoms after gastric bypass. METHODS: This was a nationwide cohort study of all adults with preoperative reflux who underwent gastric bypass in Sweden between 2006 and 2015, with complete follow-up through 2016. The outcome was remaining/recurring reflux symptoms, defined as use of proton pump inhibitors or histamine-2 receptor antagonists for >6 months after surgery. Cumulative incidence and risk factors of reflux were assessed with multivariable Poisson regression. RESULTS: Among 2454 participants (81.7% female; mean age: 46.1 years, SD: 9.8 years), who were followed for median 4.6 years (interquartile range: 3.1-6.3 years), reflux recurred in 48.8% (95% confidence interval [95% CI], 46.8-51.0) of participants within 2 years of gastric bypass and remained stable up to 10 years after surgery (yearly change in incidence rate ratio [IRR] of 1.00; 95% CI, 0.99-1.02). Risk factors for recurring reflux were high preoperative dose of anti-reflux medication (IRR 1.77; 95% CI, 1.60-1.96 compared with low dose), older age (IRR 1.12; 95% CI 1.02-1.24 comparing age >50 with <40 years), female sex (IRR 1.28; 95% CI, 1.16-1.42) and comorbidity (IRR 1.26; 95% CI, 1.14-1.39 comparing Charlson Comorbidity Index ≥2 with 0). CONCLUSIONS: Reflux symptoms decrease rapidly after gastric bypass, but around half of operated patients require continuous anti-reflux medication. The treatment efficacy of gastric bypass on reflux symptoms might have been overestimated.
引用
- Holmberg D, Santoni G, Xie S, et al. Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2019. PMID: 31165515. doi:10.1111/apt.15274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。